Illumina and Qiagen recently announced a 15-year partnership to develop next-generation sequencing-based in vitro diagnostic kits, including companion diagnostics.

Genomic services provider Novogene has signed an agreement to develop a companion diagnostic for a cancer drug under development at Chipscreen Biosciences, the Chinese companies said today.

The global immunoassay market is projected to grow at a CAGR of 5.9% from 2019 to reach USD 19.76 billion by 2025...

Diagnostics developer DiamiR said today that it has received an additional $345,000 in grant funding from the National Institute on Aging to develop a microRNA-based test for early-stage Alzheimer's disease.

Thermo Fisher Scientific today priced an underwritten offering of a series of euro- and dollar-denominated senior notes, in an aggregate principal amount of $5.7 billion.

Roche announced today its cobas Babesia blood test for individual blood donation testing has received marketing approval from the US Food and Drug Administration.

PerkinElmer said after the close of the market on Tuesday that it has entered into an agreement for a new $1 billion unsecured revolving credit facility available through Sept. 17, 2024.

Illumina plans to lay off 58 employees, according to documents filed with the State of California Employment Development Department.

DiaSorin Molecular has received CE mark for an assay that detects DNA of varicella-zoster virus (VZV) directly from swab specimens, the firm announced today.

Bio-Rad Laboratories yesterday filed another lawsuit accusing 10x Genomics of patent infringement.

In diagnostics these days, “a lot of people are after plasma,” reports Jim Averso, vice president, sales and marketing, of I.W. Tremont.

Roche has won a nod from FDA for a new diagnostic for individual blood donation testing. The Basel-Switzerland-based company’s cobas Babesia test is for use on the cobas 6800 8800 system.

Razor Genomics has developed a test enables the identification of lung cancer patients at high risk for recurrence and allows them to be treated at a time when their cancer can still be responsive to adjuvant chemotherapy.

There’s a new entrant in the liquid biopsy space. Well, sort of. Even though OncoCell MDx was formed in 2012, it hasn’t made a great deal of noise up until this year.

Today’s molecular diagnostics testing typically involves either manual processing at a reference laboratory or automated processing by preconfigured instruments in near-patient settings, Dr. Jack Regan, CEO and founder of LexaGene, said.